



15        **Abstract**

16    Digestion of starch especially the rapidly digestible starch (RDS) leads to hyperglycemia. There is  
17    a clear relationship between postprandial hyperglycemia and diet-related health problems like  
18    diabetes and obesity, and the most useful therapy for these problems is to moderate postprandial  
19    blood glucose levels. This study aimed to determine the inhibition of starch digestion activities by  
20    peptides derived from camel milk proteins and to assess the effect of their amino acids charge  
21    and/or hydrophobicity. Starch digestion by pancreatic and brush border enzymes was assessed *in*  
22    *vitro* with a peptide to starch ratio of 1:3 (w/w). Hydrolysed whey proteins were more inhibitory  
23    than hydrolysed casein. Peptides were fractionated by cation exchange chromatography (CEX)  
24    and hydrophobic interaction chromatography (HIC). The successive chromatographic separation  
25    by CEX and HIC enriched positively charged peptides with hydrophobic amino acids. Whey  
26    protein hydrolysate inhibited starch hydrolysis by 16%; peptide fractions recovered after CEX and  
27    HIC inhibited starch hydrolysis by 33 – 36%. Peptides in the active fractions were identified by  
28    LC-MS/MS and the inhibitory activity of 6 synthetic peptides was evaluated. Two of these six  
29    peptides, LALDIEIATYR and VLDELTLAR, inhibited starch hydrolysis by 34 – 37%. In  
30    conclusion, specific peptides that are produced before or during *in vitro* digestion can inhibit starch  
31    digestion and may moderate postprandial blood glucose levels *in vivo*.

32    **KEYWORDS:** Camel milk, whey protein, bioactive peptides, starch digestion inhibition, charge,  
33    hydrophobicity.

34

## 35 **1 Introduction**

36 Starch is the storage polysaccharide in seeds of many plant crops including legumes and cereals  
37 (Perin & Murano, 2017). Starch is the only polysaccharide that is hydrolyzed by human intestinal  
38 enzymes and provides 45-65% of the daily dietary energy for humans worldwide (Augustin et al.,  
39 2015). Depending on the botanical origin, starch consists of 74%-82% amylopectin and 18%-26%  
40 amylose (Englyst et al., 1992; Miao & Hamaker, 2021). Starch has been classified as non-glycemic  
41 or glycemic (Augustin et al., 2015; Hasek et al., 2018). Glycemic starch includes rapidly digestible  
42 starch (RDS) and slowly digestible starch (SDS). Non-glycemic starch or resistant starch is not  
43 hydrolysed in the small intestine but fermented in the large intestine (Englyst et al., 1992).

44 Starch is digested in two stages: the intraluminal stage, which involves hydrolysis by salivary and  
45 pancreatic  $\alpha$ -amylases; the brush border stage, which involve maltase/glucoamylase (MGAM, EC  
46 3.2.1.20/3.2.1.3) and sucrase/isomaltase (SIM, EC 3.2.1.48/3.2.1.10) as the main enzymes with  
47 activity on oligosaccharides derived from starch, followed by absorption of glucose (Zhang et al.,  
48 2015). Digestion of glycemic starch, especially RDS, leads to fast rise of blood glucose levels.  
49 Postprandial hyperglycemia is related to diet-related health problems like diabetes and obesity  
50 while slowly digestible starch (SDS) liberates glucose more slowly and is considered more  
51 beneficial than RDS (Hanefeld & Schaper, 2007).

52 The ratio of amylopectin to amylose, crystallinity, porosity, surface area, and integrity all affect  
53 starch digestibility (Miao & Hamaker, 2021). The food matrix, e.g. the presence of proteins,  
54 dietary fibre, lipids and phenolic compounds, also leads to changes in starch digestion either  
55 through inhibition of starch digestive enzyme, or by modulation of the kinetics of digesta transit  
56 (Lopez-Rubio et al., 2008; Metzler-Zebeli et al., 2010; Wolever, 2017). Helical complexes like  
57 V-type crystalline starch are produced when free fatty acids or/and monoglycerides interact with

58 amylose, resulting in crystalline amylose that is resistant to digestion (Luo et al., 2020).  
59 Interactions between starch and phenolic compounds decrease starch digestibility by several  
60 mechanisms including inhibition of pancreatic  $\alpha$ -amylase and brush border enzymes, enhancing  
61 amylose crystallinity, or by physical complexation (Li et al., 2020; Simsek et al., 2017; Sun et al.,  
62 2018). Proteins of wheat and other grains physically surround the granules of starch, limiting  
63 access of digestive enzymes (Bhattarai et al., 2018; Zhou et al., 2018). In addition, dietary fibre  
64 and peptides derived from protein hydrolysis inhibit starch digestion (Augustin et al., 2015;  
65 Layman et al., 2003).

66 Bioactive peptides are generated by hydrolysis of proteins *in vivo* and/or *ex vivo* through digestive  
67 enzymes, microbial enzymes, and microbial fermentation (Park, 2009). Bioactive peptides in milk  
68 protein hydrolysates were suggested to inhibit starch digestion by inhibition of intestinal  
69  $\alpha$ -glucosidases (Lacroix & Li-Chan, 2013; Park, 2009). *In vivo* human trials demonstrated effects  
70 of milk protein hydrolysates (Sartorius et al., 2019), casein hydrolysates (Geerts et al., 2011), and  
71 whey protein hydrolysates (Chen et al., 2020) on the postprandial glucose levels but did not  
72 identify individual peptides with inhibitory activity on starch digestion.

73 Most studies with milk-derived peptides were conducted with bovine milk and only a few studies  
74 have investigated the bioactive peptides from camel milk (El-Agamy, 2009). Camel milk whey  
75 proteins consist of a high proportion of hydrophobic amino acids and contain a high content of  
76 Phe, Val, Leu, Lys, Glu and Pro (El-Agamy, 2009; Rafiq et al., 2015). These intrinsic  
77 characteristics of whey proteins from camel milk make these promising candidates for generation  
78 of bioactive peptides that inhibit starch digestion. The aims of this study therefore were: (i) to  
79 assess the effect of enzymatic hydrolysis of proteins from camel milk on *in vitro* starch digestion,

80 (ii) to enrich active peptides by fractionation with cation exchange chromatography and  
81 hydrophobic interaction chromatography, and (iii) to determine the sequences of active peptides.

## 82 **2 Materials and methods**

### 83 **2.1 Isolation of cheese whey.**

84 Unpasteurized and lyophilized skim milk from Bactrian camels was obtained from the Inner  
85 Mongolia Agricultural University, Hohhot, China. Skim camel milk was reconstituted by dissolving  
86 the skim milk powder in water at a solid to water ratio of 1:10 (w/v) with vigorous stirring (1000  
87 rpm, 23°C) for 2h. The reconstituted milk was heated to 37°C and 1mL camel chymosin (Chr.  
88 Hansen, Bayswater, Australia) was added to 1L milk, followed by incubation at 37°C for 60min.  
89 Precipitated proteins were removed from the supernatant containing whey proteins and the  
90 caseinmacropeptide by centrifugation at 5,000×g for 60min at 4°C. The latter step was repeated 3  
91 times, and the supernatant was lyophilized and stored at -20°C until further analysis.

### 92 **2.2 Hydrolysis of casein and whey protein.**

93 Whey proteins and casein were hydrolyzed by addition of proteases from *Aspergillus oryzae*  
94 (Flavourzyme, Sigma, Canada, EC: 232-752-2). A 10% (w/v) whey or casein solution was  
95 prepared, and the pH value for solution was adjusted to 6.0 using 0.1M HCL. Flavourzyme was  
96 added at 0.05% (v/v) and the mixture was agitated with glass beads at 50°C for 24h to hydrolyze  
97 proteins. The reaction was stopped by heating to 95°C for 5min, then the hydrolysates were  
98 lyophilized and stored at -20°C for further analysis. The hydrolysis was conducted in triplicate.

### 99 **2.3 Hydrophobic interaction chromatography (HIC)**

100 Camel milk whey hydrolysates were fractionated by HIC on an Octyl Sepharose CL-4B column  
101 (1.5cm × 15cm, Octyl Sepharose CL-4B, GE Healthcare, Chicago, IL) that was linked to a UV

102 detector (220nm). Freeze-dried camel milk whey hydrolysates were dissolved in 0.1%  
103 trifluoroacetic acid (TFA) and the pH was adjusted to 6.0. Of this solution, 250mL were loaded on  
104 the column. The column was washed with 250mL distilled water (pH 6) and eluted with 250mL  
105 5% isopropanol in water with 0.1% TFA. The fractions were pooled based on the 220 and 280 nm  
106 absorbance, freeze-dried, and analyzed by starch digestibility assay as described above (Figure 1).

#### 107 **2.4 Cation exchange chromatography (CEX)**

108 Camel milk whey hydrolysates (Table 1) were fractionated by CEX on a 1.5cm × 15cm, SP-  
109 Sepharose fast flow column (GE Healthcare, Chicago, IL). Freeze-dried camel milk whey  
110 hydrolysates were dissolved in distilled water to a concentration of 1g/L and the pH was adjusted  
111 to 7.0. Of this solution, 250mL were loaded on the column and the column was washed with  
112 distilled water (pH 7). The column was eluted with a linear gradient of 0 to 2M NaCl in water and  
113 the fractionation was monitored by measuring the absorption at 220nm. The fractions were pooled  
114 based on peaks, then part of each pooled fraction was freeze-dried, and analyzed for the starch  
115 digestibility assay as described above.

116 Fraction (F1) from the CEX was further purified and sub-fractionated by HIC as described above.  
117 The column was washed with 0.1% TFA and eluted with 5% isopropanol in 0.1% TFA. The  
118 fractions were pooled based on peaks, freeze-dried, and analyzed with the starch digestibility assay  
119 as described in section 2.7. (Figure 1).

#### 120 **2.5 Peptide sequencing**

121 Fraction F1 after HIC and the pooled fractions F1\* and F2\* after CEX-HIC were selected for  
122 peptide sequencing by LC-MS/MS. Peptide sequencing was carried out by Alberta Proteomics and  
123 Mass Spectrometry Facility in the Department of Biochemistry of the University of Alberta.

124 Briefly, 50µg of sample was dissolved in 100mM ammonium bicarbonate to a concentration of  
125 1.0g/L, reduced with dithiothreitol and alkylated with iodoacetamide. Samples were then digested  
126 overnight with trypsin (2µg, Promega sequencing grade) at 37°C. After digestion, the pH of the  
127 samples was adjusted to 3-4 with formic acid, dried, dissolved in water + 0.2% formic acid, and  
128 desalted (Pierce C18 tips). The sample was additionally analysed without trypsin hydrolysis.

129 The peptides were resolved and ionized by using nano-flow HPLC (Easy-nLC 1000, Thermo  
130 Scientific) coupled to a Q Exactive Orbitrap mass spectrometer (Thermo Scientific) with an  
131 EASY-Spray capillary HPLC column (ES800A, Thermo Scientific). The mass spectrometer was  
132 operated in data-dependent acquisition mode, recording high-accuracy and high-resolution survey  
133 orbitrap spectra using external mass calibration, with a resolution of 35,000 and m/z range of 300–  
134 1700. The 12 most intense multiply charged ions were sequentially fragmented by using high  
135 energy collision induced dissociation and spectra of their fragments were recorded in the orbitrap  
136 at a resolution of 17,500. Data was processed using Proteome Discoverer 1.4 (Thermo Scientific)  
137 and the database was searched using SEQUEST (Thermo Scientific). Search parameters included  
138 a strict false discovery rate (FDR) of 0.01, a relaxed FDR of 0.05, a precursor mass tolerance of  
139 10ppm and a fragment mass tolerance of 0.01Da. Peptides were searched with carbamidomethyl  
140 cysteine as a static modification and oxidized methionine and deamidated glutamine and  
141 asparagine as dynamic modifications.

## 142 **2.6 Peptide synthesis**

143 Six short peptides identified in the most potent HIC fractions and CEX-HIC fractions were chosen  
144 for peptide synthesis. The selected peptide sequences were synthesized by Canada Peptide (Pointe-  
145 Claire, Quebec, Canada) with 92.5 – 97.9 % purity. The effect of the peptides on starch digestibility  
146 was assayed as described in section 2.7.

## 147 **2.7 *In vitro* digestibility of starch and starch-peptide mixtures**

148 Starch digestion *in vivo* simultaneously hydrolyses dietary proteins and peptides through the  
149 activity of pepsin, pancreatic enzymes, and brush border peptidases. To mimic the *in vivo* situation,  
150 the assay for starch digestibility used pancreatic enzymes and brush border enzymes that also have  
151 protease or peptidase activity. Starch (7.5mg; potato starch, Sigma, Canada) or peptide-starch  
152 mixtures (2.5mg peptide: 7.5mg starch) were suspended in 1mL of water, heated for 10min at 85°C  
153 to gelatinize the starch, and incubated at 37°C for 16h. Protein or peptide samples that were  
154 analysed are shown in Table 1. Digestion of starch and proteins or peptides was carried out by  
155 adding 0.5mg of pepsin (250U/mg, Sigma, Canada) and incubation at pH 2.0 and 37°C with  
156 agitation at 200rpm for 30min. The pH of the digesta was adjusted to pH 6.0 with 2M NaOH prior  
157 to addition of porcine pancreatic enzymes and brush border enzymes from the rat intestinal mucosa  
158 (Tsunehiro et al., 1999). In brief, 1ml of 50mM sodium maleate buffer pH 6.0 containing 0.07g  
159 porcine pancreatin (Sigma, USA; 45U/mg lipase, 42U/mg amylase, and 3.0U/mg protease) and  
160 10g/L rat small intestinal enzyme (Sigma, USA) was added to 1ml of digesta. After adding ~ 5  
161 glass beads (5mm diameter), the reaction mixture was incubated at 37°C and pH 6 for 4h with  
162 agitation at 200rpm. The digestion process was stopped by heating to 95°C for 4min. The samples  
163 were cooled on ice and centrifuged at 5, 000 ×g for 5min at 4°C. The glucose concentration for  
164 samples and controls was measured with the D-glucose (GOPOD-format) kit (Megazyme, Bary,  
165 Ireland) (Figure 1).

## 166 **2.8 Statistical Analysis.**

167 Starch digestibility assay was performed in triplicate biological repeats with three technical  
168 repeats, and the results are presented as means ± standard error. To determine the statistical  
169 differences between the samples, p-values were calculated using Tukey Pairwise Comparisons at



170 95% Confidence in Minitab 19 (The differences between the conditions are considered significant  
171 if p-value < 0.05).

## 172 **3 Results**

### 173 **3.1 Starch digestibility inhibition of camel whey and whey hydrolysates.**

174 The starch digestibility assay was applied to starch alone or mixtures of peptides / proteins and  
175 starch in a ratio of 1:3 (w/w peptide: starch). The digestibility assay included addition of pepsin,  
176 pancreatic enzymes, and brush border enzymes to mimic the enzymes involved in starch and  
177 protein digestion in the digestive tract. It was previously shown that the activity of brush border  
178 glycosyl hydrolases from rat intestinal mucosa corresponds the activity of human brush border  
179 enzymes (Oku et al., 2011).

180 Whey and casein inhibited starch hydrolysis by about 10 and 7%, respectively (Table 1).  
181 Enzymatic hydrolysis of whey and casein with flavourzyme increased the inhibition of starch  
182 hydrolysis by whey and casein hydrolysates to about 17 and 11%, respectively (Table 1).  
183 Hydrolyzed whey consists of 13.6% proteins or peptides while the protein or peptide content in  
184 the casein hydrolysate is more than 85%, therefore, any peptides in the whey fraction presumably  
185 are more active and subsequent analyses focused on whey hydrolysates.

### 186 **3.2 Purification of Bactrian camel whey hydrolysate.**

187 Peptides obtained by Flavourzyme hydrolysis of camel whey proteins were first fractionated by  
188 HIC. Fractions were characterized with respect to the inhibition of starch hydrolysis. Fractionation  
189 of by HIC resulted in five fractions (Figure 2). Among these fractions, fraction 1 (F1) was most  
190 inhibitory to starch hydrolysis (Figure 3).

191 In addition, peptides in the whey hydrolysate were fractionated by CEX. Whey hydrolysate  
192 purified by CEX was collected in four fractions (Figure 4A). The chromatogram and the inhibition  
193 of starch hydrolysis by the fractions are shown in Figure 4B and 5B, respectively. Fraction F1  
194 from CEX exhibited the highest inhibitory activity on starch hydrolysis (Fig. 5B) and was  
195 subsequently fractionated by HIC (CEX-HIC). Of the fractions eluting from the HIC column,  
196 fractions F1\* and F2\* were most inhibitory to starch hydrolysis. These two fractions were pooled  
197 and selected for peptide sequencing by LC-MS/MS. Peptides in fraction F1 eluting from HIC was  
198 also sequenced for comparison.

### 199 **3.3 Peptide sequences in fractions inhibiting starch hydrolysis.**

200 The fractionated peptides were sequenced by LC/MS/MS after trypsin digestion. A total of 22  
201 peptides were identified in fraction F1 after HIC separation. Peptide sequences consisted of 7-24  
202 amino acids with molecular weights (Mw) ranging from 994 to 2933Da (Table 2). In the pooled  
203 fractions F1\* and F2\* obtained after fractionation on CEX and HIC, 13 peptides were identified  
204 after trypsin digestion. In addition, 2 peptides were identified in a sample that was analyzed  
205 without a trypsin digestion step. The molecular weights of the peptide sequences ranged from 956  
206 to 1708Da, and the peptides contained 8-19 amino acids (Table 3).

### 207 **3.4 Inhibition of starch hydrolysis by synthesized peptides**

208 The starch digestibility assay as described above was applied to the selected synthesized peptides  
209 sequences to determine their inhibitory activity on starch hydrolysis. All sequences matched  
210 *Camelus bactrianus* proteins with 100% identity and coverage (Table 4). Table 4 illustrates that  
211 two sequences that were identified after fractionation on HIC and CEX and HIC; LALDIEIATYR  
212 (LR11) and VLDELTLAR (VR9) were as active as the entire fraction. LR11 and VR9 inhibited

213 starch hydrolysis by about 37 and 33%, respectively. The remaining peptides were inactive or  
214 much less active (Table 4). The two active peptides carried a single negative charge at neutral pH  
215 and included 4 – 6 hydrophobic amino acids. Peptides with lower activity differed in their net  
216 charge at neutral pH (uncharged or positively charged) and/or included only 1 – 3 hydrophobic  
217 amino acids.

#### 218 **4 Discussion**

219 Protein and peptides can delay starch digestion by inhibition of the enzymes responsible for starch  
220 digestion, such as  $\alpha$ -amylase,  $\alpha$ -glucosidase (Augustin et al., 2015; Gangoiti et al., 2018; Layman  
221 et al., 2003; Yu et al., 2012). This study demonstrates that some of the peptides derived from camel  
222 milk whey protein also inhibit starch digestion. Purification and fractionation of camel milk whey  
223 protein peptides depending on the content of hydrophobic and positively charged amino acids  
224 strongly increased the inhibition of starch digestion. For two of the peptides, inhibition of starch  
225 digestion was confirmed by assays with chemically synthesized peptides.

226 Camel milk whey protein is not as well studied as bovine milk whey protein and the biological  
227 activities of bioactive peptides derived from camel milk whey protein are not fully explored (Jafar  
228 et al., 2018). The *in vitro* and *in vivo* studies reported that the antihyperglycemic activity of bovine  
229 whey protein hydrolysates are higher than that of the casein hydrolysates (Park, 2009; Sartorius et  
230 al., 2019). Pepsin-treated bovine  $\alpha$ -lactalbumin exhibited the highest antihyperglycemic activity  
231 compared to other pepsin-treated whey proteins including bovine serum albumin,  $\beta$ -lactoglobulin,  
232 lactoferrin, and whey protein isolate, whereas the  $\beta$ -lactoglobulin showed the lowest  
233 antihyperglycemic activity (Lacroix & Li-Chan, 2013). We confirm a higher activity of whey  
234 proteins for casein and whey protein hydrolysates from camel milk whey. Bactrian camel milk  
235 whey hydrolysates with 13.6% protein content showed an inhibition of starch hydrolysis that was

236 higher than the inhibition by a casein hydrolysate. The fractionation of the camel milk whey protein  
237 hydrolysate by HIC or by CEX-HIC further increased the activity more than two-fold (Table 1),  
238 suggesting that charged and hydrophobic amino acids enhance activity.

239 Inhibition of starch digestive enzymes has been reported for protein hydrolysates and peptides  
240 derived from albumin (Yu et al., 2012), legumes (Ngoh & Gan, 2016), cumin (Siow & Gan, 2016),  
241 and milk (Lacroix & Li-Chan, 2013) but only few studies reported specific peptide sequences with  
242 inhibitory activity. The cumin seed derived peptide FFRSKLLSDGAAAAGALLPQYW  
243 inhibited  $\alpha$ -amylase by 25% (Siow & Gan, 2016). KLPGF derived from albumin inhibited  
244  $\alpha$ -amylase and  $\alpha$ -glucosidase activities with  $IC_{50}$  values of about 120 and 59  $\mu$ M, respectively (Yu  
245 et al., 2012). We identified LALDIEIATYR and VLDELTLAR as peptides with the highest  
246 inhibitory activity on starch hydrolysis; the remaining synthesized peptides had only limited  
247 inhibitory activity on starch hydrolysis (Table 4). Peptides from camel whey proteins with *in vitro*  
248 inhibitory activity on digestive glucosidases thus contain one or more negatively charged residues  
249 (E or D), one positively charged residue (K or R) with a single negative charge at physiological  
250 pH. Moreover, aromatic or aliphatic hydrophobic residues (I, V, L, Y, F or W) account for about  
251 45% (4/9 and 5/11) of the amino acids.  $\alpha$ -Lactalbumin is the major component of camel milk whey  
252 protein constituting about 47% (Laleye et al., 2008) but peptides that inhibited intestinal  
253  $\alpha$ -glucosidases were derived from minor whey proteins (Table 4), which further supports that  
254 inhibitory activity is specific for the peptide sequence.

255 Peptides that inhibit starch digestion act locally in the gastrointestinal tract (Xu et al., 2019), and  
256 the bioavailability of these peptides is affected by digestive enzymes in the gastrointestinal tract,  
257 metabolism, and absorption. Our assay differs from previous studies by including brush border  
258 enzymes in the *in vitro* assay for starch digestion. This approach has the advantage of simulating

259 the *in vivo* digestion more closely, however, because the commercial preparation of brush border  
260 enzymes also includes brush border peptidases, the peptides used may have been further modified  
261 during the digestion assay. Pepsin hydrolysis in the stomach is the first step in food protein  
262 digestion and proteins are then further hydrolysed by the pancreatic proteases trypsin and  
263 chymotrypsin, and by brush border peptidases (Hooton et al., 2015). Brush border enzymes that  
264 contribute to peptide hydrolysis include the peptidyl dipeptidase, aminopeptidase N, dipeptidyl  
265 aminopeptidase IV,  $\gamma$ -glutamyltranspeptidase, aminopeptidase A, and carboxypeptidase (Hooton  
266 et al., 2015; Mentlein, 2004; Yoshioka et al., 1988). The biological activity of peptides depends  
267 on the degree of hydrolysis by these digestive enzymes (Xu et al., 2019; Yoshioka et al., 1988;  
268 Zambrowicz et al., 2015). Proteins with high content of proline are resistant to gastric and  
269 pancreatic peptidases, and proline-rich peptides are thus most likely to escape the digestion and to  
270 reach the intestinal membrane in relatively intact sequence to face the brush border enzymes  
271 (Mentlein, 2004; Yoshioka et al., 1988). Peptides with multiple proline residues including IPP  
272 (Nongonierma & FitzGerald, 2016), VPP (Ten Have et al., 2015) and HLPLP (Sánchez-Rivera et  
273 al., 2014) have been detected in the plasma of human and animals. Only few of the peptides in the  
274 active fractions and none of the synthetic peptides with high inhibitory activity included proline in  
275 their sequence (Tables 2 – 4), however, because peptides that inhibit starch digestion may be active  
276 in the luminal stage of starch digestion by pancreatic amylases (Zhang et al., 2015), resistance to  
277 hydrolysis by brush border enzymes is not a prerequisite for activity. Whey-derived peptides were  
278 shown to inhibit brush border peptidases (Lacroix & Li-Chan, 2014), which may have increased  
279 the time needed for hydrolysis of peptides or peptide fractions that were assessed in the present  
280 study with respect to *in vitro* activity.

281 Several *in vivo* studies demonstrated that dietary peptides or proteins may reduce the relative  
282 glycemic response. VAGTWY from trypsin-treated bovine whey proteins showed significant  
283 decrease in postprandial glucose level in mice with an IC<sub>50</sub> value about 174 μM (Uchida et al.,  
284 2011). Bovine whey proteins were more effective in reducing postprandial blood glucose levels in  
285 humans than other proteins (Wolever, 2017) but the effect was also observed with glucose rather  
286 than starch as carbohydrate source (Gunnerud et al., 2013; Lan-Pidhainy & Wolever, 2010) and  
287 thus relates to mechanisms that are independent of the rate of starch hydrolysis. Human intervention  
288 studies with bovine casein hydrolysates or whey protein hydrolysates also consistently reported  
289 reduced postprandial blood glucose level (Geerts et al., 2011; Manders et al., 2006; Sartorius et al.,  
290 2019). Because the available clinical studies all used bovine milk but did not compare different  
291 peptides or peptide fractions, and did not relate the *in vivo* effect on the relative glycemic response  
292 to the rate of starch hydrolysis in the small intestine, it is not possible to relate the *in vitro* inhibitory  
293 effect on starch digestion that was observed in the present study to these clinical data. Moreover,  
294 while a protein to starch ratio of 1:3 (w/w) may match the dietary intake of protein (hydrolysates)  
295 and starch, the same ratio by far exceeds the intake of peptide fractions or synthetic peptides as  
296 dietary supplement. The contribution of the inhibition of luminal or brush border glucosyl  
297 hydrolases by whey protein-derived peptides on the glycemic response thus remains subject to  
298 future investigations.

## 299 **Conclusion**

300 The prevalence of food-related chronic diseases including diabetes mellitus has increased  
301 worldwide. Rapid digestion of dietary starch leads to hyperglycemia that may lead to the  
302 development of insulin resistance and diabetes mellitus. Delaying carbohydrate digestion is an  
303 accepted approach as a treatment of type-2 diabetes. The present study identified specific whey

304 peptides from camel milk with inhibitory activity on *in vitro* starch hydrolysis. This finding may  
305 inform future studies to improve the use of (camel) milk proteins or protein hydrolysates in dietary  
306 intervention strategies to reduce the risk of insulin resistance and diabetes.

### 307 **Acknowledgements**

308 We acknowledge the Natural Sciences and Engineering Research Council of Canada (NSERC)  
309 and Canada Research Chairs (CRC) for their funding. We are grateful for Chr. Hansen, Australia  
310 for providing camel chymosin.

### 311 **References**

- 312 Augustin, L. S. A., Kendall, C. W. C., Jenkins, D. J. A., Willett, W. C., Astrup, A., Barclay, A.  
313 W., Björck, I., Brand-Miller, J. C., Brighenti, F., Buyken, A. E., Ceriello, A., La Vecchia, C.,  
314 Livesey, G., Liu, S., Riccardi, G., Rizkalla, S. W., Sievenpiper, J. L., Trichopoulou, A.,  
315 Wolever, T. M. S., ... Poli, A. (2015). Glycemic index, glycemic load and glycemic response:  
316 An International Scientific Consensus Summit from the International Carbohydrate Quality  
317 Consortium (ICQC). *Nutrition, Metabolism and Cardiovascular Diseases*, 25(9), 795–815.  
318 <https://doi.org/10.1016/J.NUMECD.2015.05.005>
- 319 Bhattarai, R. R., Dhital, S., Mense, A., Gidley, M. J., & Shi, Y. C. (2018). Intact cellular structure  
320 in cereal endosperm limits starch digestion in vitro. *Food Hydrocolloids*, 81, 139–148.  
321 <https://doi.org/10.1016/J.FOODHYD.2018.02.027>
- 322 Chen, Y. C., Smith, H. A., Hengist, A., Chrzanowski-Smith, O. J., Mikkelsen, U. R., Carroll, H.  
323 A., Betts, J. A., Thompson, D., Saunders, J., & Gonzalez, J. T. (2020). Co-ingestion of whey  
324 protein hydrolysate with milk minerals rich in calcium potently stimulates glucagon-like  
325 peptide-1 secretion: an RCT in healthy adults. *European Journal of Nutrition*, 59(6), 2449–

326 2462. <https://doi.org/10.1007/S00394-019-02092-4>

327 El-Agamy, E. I. (2009). *Bioactive components in camel milk. Bioactive components in milk and*  
328 *dairy products* . (pp. 159–192). Wiley-Blackwell.

329 Englyst, H. N., Kingman, S. M., & Cummings, J. H. (1992). Classification and measurement of  
330 nutritionally important starch fractions. *European Journal of Clinical Nutrition*, 46 Suppl  
331 2(SUPPL. 2), S33-50. <https://europepmc.org/article/med/1330528>

332 Gangoiti, J., Corwin, S. F., Lamothe, L. M., Vafiadi, C., Hamaker, B. R., & Dijkhuizen, L. (2018).  
333 Synthesis of novel  $\alpha$ -glucans with potential health benefits through controlled glucose release  
334 in the human gastrointestinal tract. *Critical Reviews in Food Science and Nutrition*, in press.  
335 <https://doi.org/10.1080/10408398.2018.1516621>

336 Geerts, B. F., Van Dongen, M. G. J., Flameling, B., Moerland, M. M., De Kam, M. L., Cohen, A.  
337 F., Romijn, J. A., Gerhardt, C. C., Kloek, J., & Burggraaf, J. (2011). Hydrolyzed casein  
338 decreases postprandial glucose concentrations in T2DM patients irrespective of leucine  
339 content. *Taylor & Francis*, 8(3), 280–292. <https://doi.org/10.3109/19390211.2011.593617>

340 Gunnerud, U. J., Östman, E. M., & Björck, I. M. E. (2013). Effects of whey proteins on glycaemia  
341 and insulinaemia to an oral glucose load in healthy adults; a dose–response study. *European*  
342 *Journal of Clinical Nutrition* 2013 67:7, 67(7), 749–753.  
343 <https://doi.org/10.1038/ejcn.2013.88>

344 Hanefeld, M., & Schaper, F. (2007). The Role of Alpha-Glucosidase Inhibitors (Acarbose).  
345 *Pharmacotherapy of Diabetes: New Developments: Improving Life and Prognosis for*  
346 *Diabetic Patients*, 143–152. [https://doi.org/10.1007/978-0-387-69737-6\\_13](https://doi.org/10.1007/978-0-387-69737-6_13)

347 Hasek, L. Y., Phillips, R. J., Zhang, G., Kinzig, K. P., Young Kim, C., Powley, T. L., & Hamaker,



348 B. R. (2018). Dietary slowly digestible starch triggers the gut-brain axis in obese rats with  
349 accompanied reduced food intake. *Mol Nutr Food Res*, 62(5).  
350 <https://doi.org/10.1002/mnfr.201700117>

351 Hooton, D., Lentle, R., Monro, J., Wickham, M., & Simpson, R. (2015). The secretion and action  
352 of brush border enzymes in the mammalian small intestine. In *Reviews of physiology,*  
353 *biochemistry and pharmacology* (Vol. 168, pp. 59–118).  
354 [https://doi.org/10.1007/112\\_2015\\_24](https://doi.org/10.1007/112_2015_24)

355 Jafar, S., Kamal, H., Mudgil, P., Hassan, H. M., & Maqsood, S. (2018). Camel whey protein  
356 hydrolysates displayed enhanced cholesteryl esterase and lipase inhibitory, anti-hypertensive  
357 and anti-haemolytic properties. *LWT*, 98, 212–218.  
358 <https://doi.org/10.1016/J.LWT.2018.08.024>

359 Lacroix, I. M. E., & Li-Chan, E. C. Y. (2013). Inhibition of dipeptidyl peptidase (DPP)-IV and  $\alpha$ -  
360 glucosidase activities by pepsin-treated whey proteins. *Journal of Agricultural and Food*  
361 *Chemistry*, 61(31), 7500–7506. <https://doi.org/10.1021/JF401000S>

362 Lacroix, I. M. E., & Li-Chan, E. C. Y. (2014). Isolation and characterization of peptides with  
363 dipeptidyl peptidase-IV inhibitory activity from pepsin-treated bovine whey proteins.  
364 *Peptides*, 54, 39–48. <https://doi.org/10.1016/J.PEPTIDES.2014.01.002>

365 Laleye, L. C., Jobe, B., & Wasesa, A. A. H. (2008). Comparative study on heat stability and  
366 functionality of camel and bovine milk whey proteins. *Journal of Dairy Science*, 91(12),  
367 4527–4534. <https://doi.org/10.3168/JDS.2008-1446>

368 Lan-Pidhainy, X., & Wolever, T. M. S. (2010). The hypoglycemic effect of fat and protein is not  
369 attenuated by insulin resistance. *The American Journal of Clinical Nutrition*, 91(1), 98–105.

370 <https://doi.org/10.3945/AJCN.2009.28125>

371 Layman, D. K., Shiue, H., Sather, C., Erickson, D. J., & Baum, J. (2003). Increased Dietary Protein  
372 Modifies Glucose and Insulin Homeostasis in Adult Women during Weight Loss. *The Journal*  
373 *of Nutrition*, 133(2), 405–410. <https://doi.org/10.1093/JN/133.2.405>

374 Li, M., Griffin, L. E., Corbin, S., Neilson, A. P., & Ferruzzi, M. G. (2020). Modulating phenolic  
375 bioaccessibility and glycemic response of starch-based foods in Wistar rats by physical  
376 complexation between starch and phenolic acid. *Journal of Agricultural and Food Chemistry*,  
377 68(46), 13257–13266. <https://doi.org/10.1021/acs.jafc.0c01387>

378 Lopez-Rubio, A., Flanagan, B. M., Shrestha, A. K., Gidley, M. J., & Gilbert, E. P. (2008).  
379 Molecular rearrangement of starch during in vitro digestion: Toward a better understanding  
380 of enzyme resistant starch formation in processed starches. *Biomacromolecules*, 9(7), 1951–  
381 1958. <https://doi.org/10.1021/BM800213H>

382 Luo, S., Zeng, Z., Mei, Y., Huang, K., Wu, J., Liu, C., & Hu, X. (2020). Improving ordered  
383 arrangement of the short-chain amylose-lipid complex by narrowing molecular weight  
384 distribution of short-chain amylose. *Carbohydrate Polymers*, 240, 116364.  
385 <https://doi.org/10.1016/J.CARBPOL.2020.116359>

386 Manders, R. J. F., Praet, S. F. E., Meex, R. C. R., Koopman, R., De Roos, A. L., Wagenmakers,  
387 A. J. M., Saris, W. H. M., & Van Loon, L. J. C. (2006). Protein hydrolysate/leucine co-  
388 ingestion reduces the prevalence of hyperglycemia in type 2 diabetic patients. *Diab. Care*,  
389 29, 2721–2722. <https://doi.org/10.2337/dc06-1424>

390 Mentlein, R. (2004). Cell-surface peptidases. *International Review of Cytology*, 235, 165–213.  
391 [https://doi.org/10.1016/S0074-7696\(04\)35004-7](https://doi.org/10.1016/S0074-7696(04)35004-7)

392 Metzler-Zebeli, B. U., Hooda, S., Pieper, R., Zijlstra, R. T., Van Kessel, A. G., Mosenthin, R., &  
393 Gänzle, M. G. (2010). Nonstarch polysaccharides modulate bacterial microbiota, pathways  
394 for butyrate production, and abundance of pathogenic escherichia coli in the pig  
395 gastrointestinal tract. *Applied and Environmental Microbiology*, 76(11), 3692–3701.  
396 <https://doi.org/10.1128/AEM.00257-10>

397 Miao, M., & Hamaker, B. R. (2021). Food matrix effects for modulating starch bioavailability.  
398 *Annual Review of Food Science and Technology*, 12(1). [https://doi.org/10.1146/annurev-  
399 food-070620-013937](https://doi.org/10.1146/annurev-<br/>399 food-070620-013937)

400 Ngoh, Y. Y., & Gan, C. Y. (2016). Enzyme-assisted extraction and identification of antioxidative  
401 and  $\alpha$ -amylase inhibitory peptides from Pinto beans (*Phaseolus vulgaris* cv. Pinto). *Food*  
402 *Chemistry*, 190, 331–337. <https://doi.org/10.1016/J.FOODCHEM.2015.05.120>

403 Nongonierma, A. B., & FitzGerald, R. J. (2016). Strategies for the discovery, identification and  
404 validation of milk protein-derived bioactive peptides. *Trends in Food Science and*  
405 *Technology*, 50, 26–43. <https://doi.org/10.1016/J.TIFS.2016.01.022>

406 Oku, T., Tanabe, K., Ogawa, S., Sadamori, N., & Nakamura, S. (2011). Similarity of hydrolyzing  
407 activity of human and rat small intestinal disaccharidases. *Clinical and Experimental*  
408 *Gastroenterology*, 4, 155–161. <https://doi.org/10.2147/CEG.S19961>

409 Park, Y. W. (2009). *Bioactive components in milk and dairy products*. Wiley-Blackwell.

410 Perin, D., & Murano, E. (2017). Starch polysaccharides in the human diet: effect of the different  
411 source and processing on its absorption. *Natural Product Communications*, 12(4), 837–853.

412 Rafiq, S., Huma, N., Pasha, I., Sameen, A., Mukhtar, O., & Khan, M. I. (2015). Chemical  
413 composition, nitrogen fractions and amino acids profile of milk from different animal

414 species. *Asian-Australasian Journal of Animal Sciences*, 29(7), 1022–1028.  
415 <https://doi.org/10.5713/AJAS.15.0452>

416 Sánchez-Rivera, L., Ares, I., Miralles, B., Gómez-Ruiz, J. Á., Recio, I., Martínez-Larrañaga, M.  
417 R., Anadón, A., & Martínez, M. A. (2014). Bioavailability and kinetics of the  
418 antihypertensive casein-derived peptide HLPLP in rats. *Journal of Agricultural and Food*  
419 *Chemistry*, 62(49), 11869–11875. <https://doi.org/10.1021/jf5035256>

420 Sartorius, T., Weidner, A., Dharsono, T., Wilhelm, M., Boulier, A., & Brown, C. S. (2019).  
421 Postprandial effects of a proprietary milk protein hydrolysate containing bioactive peptides  
422 in prediabetic subjects. *Nutrients*, 11(7), 1700–1717. <https://doi.org/10.3390/NU11071700>

423 Simsek, M., Quezada-Calvillo, R., Nichols, B. L., & Hamaker, B. R. (2017). Phenolic compounds  
424 increase the transcription of mouse intestinal maltase-glucoamylase and sucrase-isomaltase.  
425 *Food & Function*, 8(5), 1915–1924. <https://doi.org/10.1039/C7FO00015D>

426 Siow, H. L., & Gan, C. Y. (2016). Extraction, identification, and structure–activity relationship of  
427 antioxidative and  $\alpha$ -amylase inhibitory peptides from cumin seeds (*Cuminum cyminum*).  
428 *Journal of Functional Foods*, 22, 1–12. <https://doi.org/10.1016/J.JFF.2016.01.011>

429 Sun, L., Warren, F. J., & Gidley, M. J. (2018). Soluble polysaccharides reduce binding and  
430 inhibitory activity of tea polyphenols against porcine pancreatic  $\alpha$ -amylase. *Food*  
431 *Hydrocolloids*, 79, 63–70. <https://doi.org/10.1016/J.FOODHYD.2017.12.011>

432 Ten Have, G. A. M., Van Der Pijl, P. C., Kies, A. K., & Deutz, N. E. P. (2015). Enhanced lacto-  
433 tri-Peptide bio-availability by co-ingestion of macronutrients. *PLOS ONE*, 10(6), e0130638.  
434 <https://doi.org/10.1371/JOURNAL.PONE.0130638>

435 Tsunehiro, J., Okamoto, K., Furuyama, Y., Yatake, T., & Kaneko, T. (1999). Digestibility of the

436 hydrogenated derivative of an isomaltooligosaccharide mixture by rats. *Bioscience,*  
437 *Biotechnology, and Biochemistry*, 63, 1515–1521. <https://doi.org/10.1271/bbb.63.1515>

438 Uchida, M., Ohshiba, Y., & Mogami, O. (2011). Novel dipeptidyl peptidase-4-inhibiting peptide  
439 derived from  $\beta$ -lactoglobulin. *Journal of Pharmacological Sciences*, 117(1), 63–66.  
440 <https://doi.org/10.1254/JPHS.11089SC>

441 Wolever, T. M. S. (2017). Effect of macronutrients on the glycemic index. *The American Journal*  
442 *of Clinical Nutrition*, 106(2), 704–705. <https://doi.org/10.3945/AJCN.117.158055>

443 Xu, Q., Hong, H., Wu, J., & Yan, X. (2019). Bioavailability of bioactive peptides derived from  
444 food proteins across the intestinal epithelial membrane: A review. *Trends in Food Science &*  
445 *Technology*, 86, 399–411. <https://doi.org/10.1016/J.TIFS.2019.02.050>

446 Yoshioka, M., Erickson, R. H., & Kim, Y. S. (1988). Digestion and assimilation of proline-  
447 containing peptides by rat intestinal brush border membrane carboxypeptidases. Role of the  
448 combined action of angiotensin-converting enzyme and carboxypeptidase P. *The Journal of*  
449 *Clinical Investigation*, 81(4), 1090–1095. <https://doi.org/10.1172/JCI113421>

450 Yu, Z., Yin, Y., Zhao, W., Liu, J., & Chen, F. (2012). Anti-diabetic activity peptides from albumin  
451 against  $\alpha$ -glucosidase and  $\alpha$ -amylase. *Food Chemistry*, 135(3), 2078–2085.  
452 <https://doi.org/10.1016/J.FOODCHEM.2012.06.088>

453 Zambrowicz, A., Pokora, M., Setner, B., Dąbrowska, A., Szołtysik, M., Babij, K., Szewczuk, Z.,  
454 Trziszka, T., Lubec, G., & Chrzanowska, J. (2015). Multifunctional peptides derived from an  
455 egg yolk protein hydrolysate: isolation and characterization. *Amino Acids*, 47(2), 369.  
456 <https://doi.org/10.1007/S00726-014-1869-X>

457 Zhang, G., Hasek, L. Y., Lee, B. H., & Hamaker, B. R. (2015). Gut feedback mechanisms and

458 food intake: a physiological approach to slow carbohydrate bioavailability. *Food & Function*,  
459 6(4), 1072–1089. <https://doi.org/10.1039/C4FO00803K>

460 Zhou, X., Ying, Y., Hu, B., Pang, Y., & Bao, J. (2018). Physicochemical properties and  
461 digestibility of endosperm starches in four indica rice mutants. *Carbohydrate Polymers*, 195,  
462 1–8. <https://doi.org/10.1016/J.CARBPOL.2018.04.070>

463

464 **Figure legends**

465 **Figure 1.** Flow diagram for the isolation of bioactive peptide from camel milk whey protein.

466 **Figure 2.** Fractionation of peptides obtained by hydrolysis of camel whey with flavourzyme on  
467 Octyl Sepharose CL-4B column (hydrophobic interaction chromatogram; HIC). The column was  
468 eluted with 5% isopropanol. The volume of each fraction was 5mL. Fractions are labeled with S,  
469 W, F1, F2 and F3 to designate elution during sample loading, washing, and eluate that was pooled  
470 in fractions F1, F2 and F3. The fraction that was selected for peptide sequencing is underlined.

471 **Figure 3.** Inhibition of starch hydrolysis by peptides obtained by hydrolysis of camel whey with  
472 flavourzyme and fractionation on an Octyl Sepharose CL-4B column (hydrophobic interaction  
473 chromatogram; HIC). The inhibitory activity is expressed as % reduction relate to starch hydrolysis  
474 without peptide addition. Fractions are labeled with S, W, F1, F2 and F3 to designate elution during  
475 sample loading, washing, and eluate that was pooled in fractions F1, F2 and F3.

476 **Figure 4. Panel A:** Fractionation of peptides obtained by hydrolysis of camel whey with  
477 flavourzyme on SP- Sepharose fast flow cation exchange chromatography (CEX). **Panel B:**  
478 Fractionation of F1 eluting from CEX on an Octyl Sepharose CL-4B column (hydrophobic  
479 interaction chromatogram; HIC). The volume of each fraction was 5mL. Fractions are labeled with  
480 S, W, F1, F2 and F3 to designate elution during sample loading, washing, and eluate that was  
481 pooled in fractions F1, F2 and F3. Fractions eluting from the HIC column are designated with an  
482 asterisk; fractions that were selected for further fractionation or peptide sequencing are underlined.

483 **Figure 5.** Inhibition of starch hydrolysis by peptides obtained by hydrolysis of camel whey with  
484 flavourzyme and fractionation. **Panel A.** Fractions obtained with a SP- Sepharose fast flow cation  
485 exchange (CEX) column. **Panel B.** Fractions after separation on CEX and subsequent separation

486 of fraction F1 on an Octyl Sepharose CL-4B column (hydrophobic interaction chromatography;  
487 HIC). The inhibitory activity is expressed as % reduction relate to starch hydrolysis without  
488 peptide addition. Fractions are labeled with S, W, F1, F2 and F3 to designate elution during sample  
489 loading, washing, and eluate that was pooled in fractions F1, F2 and F3.



**Table 1.** Peptide recovery after chromatography on SP-Sepharose fast flow column (cation exchange chromatography; CEX) and on Octyl Sepharose CL-4B column (hydrophobic interaction chromatography; HIC), and inhibition of starch digestion of collected fractions (peptides) at the ratio 1:3 (w/w peptide: starch) respectively. The intact and hydrolyzed casein and whey protein sample analyses were performed in triplicate and fractions were collected in duplicate.

<b>Sample</b>	<b>Amount of protein or % of protein recovered after chromatography</b>	<b>Inhibition of starch hydrolysis</b>
Camel milk	--	not determined
Casein	--	7.6% ±1.1
Whey	--	10.1% ±0.9
Hydrolyzed casein	--	11.3% ±0.9
Hydrolyzed whey	250mg, corresponding to 34mg whey protein	16.5% ±0.2
Fraction 1 after HIC	32%	26.9% ±0.1
Fraction 1 after CEX	86%	24.1% ±0.1
Fraction F1* after CEX and HIC	45%	32.8% ±0.4
Fraction F2* after CEX and HIC	09%	35.7% ±0.3

**Table 2.** Sequences of peptides in camel whey protein hydrolysates in fraction F1 obtained after separation on an Octyl Sepharose CL-4B hydrophobic interaction column. Peptides were sequenced by LC-MS/MS after trypsin hydrolysis.

Sequence	RT (min)	m/z	pI
VTMQNLNDR	13.30	1090.53	6.61
<u>IRDWYQR<sup>a)</sup></u>	13.35	1036.53	9.84
<u>LVPVICH</u> R	13.47	993.57	8.86
GFSSGSVVVSGGSR	13.54	1254.61	10.84
<u>LASYLDK</u> V	14.64	1064.61	9.74
<u>YFCDNQETISS</u> K	14.65	1491.64	3.93
ALEEANADLEVK	16.31	1301.66	3.54
<u>IRLENEIQ</u> TYR	16.60	1434.77	6.96
<u>FLEQQNQVLQ</u> TK	16.82	1475.79	6.61
<u>FASFIDK</u> V	17.27	1082.60	9.87
<u>RHPEYAVSLLL</u> R	18.90	1453.83	9.54
DAEAWFNEK	19.64	1109.49	3.69
VLDELTLAR	19.79	1029.59	3.93
<u>EYGLFQINN</u> K	20.68	1225.62	6.79
WELLQQVNTSTR	22.06	1475.75	6.74
<u>VVSVLTIQHODWLTG</u> K	22.25	1824.01	7.77
<u>NMFETPFL</u> AR	23.81	1225.60	6.44
LALDIEIATYR	24.15	1277.71	3.39
<u>FLEQQNQVLQTKWELLQQVNTSTR</u>	24.72	2932.52	6.61
SLDLDSIIAEVK	27.38	1302.72	6.61
<u>VNLFDIPL</u> EVQYVR	29.23	1704.94	6.61
<u>LALDVEI</u> ATYR	57.04	1263.70	6.61

<sup>a)</sup>Sequences that were not identified after additional fractionation on a cation exchange column

(Table 3) are underlined.

**Table 3.** Sequences of peptides identified in camel whey protein hydrolysates in the pooled fractions F1\* and F2\* after separation on SP-Sepharose fast flow column (CEX), followed by separation on an Octyl Sepharose CL-4B column (HIC). Peptides were sequenced by LC-MS/MS after trypsin hydrolysis unless otherwise specified.

Sequence	Retention time (min)	m/z	pI <sup>a)</sup>
NKYEDEINKR	10.72	1308.66	6.61
VTMQNLNDR	13.25	1090.54	6.61
GFSSGSAVVSSGSR	13.43	1254.61	10.84
YEELQVTAGR	15.32	1165.59	4.15
ALEEANADLEVK	16.20	1301.67	3.54
YEELQITAGR	16.79	1179.61	4.15
WTLLQEQGTK	18.67	1203.64	6.73
DAEAWFNEK	19.41	1109.49	3.69
VLDELTLAR	19.59	1029.59	3.93
GSLGGGFSSGGFSGGSFSR	20.23	1707.77	10.84
WELLQQVNTSTR	21.84	1475.75	6.74
LALDIEIATYR	24.00	1277.71	3.93
SLDLDSIIAEVK	27.17	1302.72	3.54
KKAGVLDYETFTK <sup>b)</sup>	6.35	1499.81	9.44
KHSTKGLGK <sup>b)</sup>	14.76	955.57	10.98


<sup>a)</sup>calculated on <https://pepcalc.com/>

<sup>b)</sup> these peptides were identified in samples that were not hydrolyzed with trypsin prior to LC-MS/MS analysis.


**Table 4.** Starch digestibility inhibition (%) of synthesized peptides identified in camel whey protein hydrolysates after separation by cation exchange chromatography and hydrophobic interaction chromatogram or just by hydrophobic interaction chromatography. Peptides synthesized by Canada Peptide company, Pointe-Claire, Quebec, Canada.

Camel Peptide sequences	Uniprot Acc. #	Camel Protein <sup>a)</sup>	Peptide source (column)	pI	Starch digestibility inhibition%
LALDIEIATYR	S9WX05	Keratin like protein	HIC and CEX+HIC	3.93	37.4 ± 1.4 <sup>a</sup>
VLDELTLAR	S9XAP9	Keratin like protein	HIC and CEX+HIC	3.93	33.6 ± 2.4 <sup>a</sup>
DAEAWFNEK	S9WUY9	Keratin like protein	HIC and CEX+HIC	3.69	5.5 ± 2.1 <sup>b</sup>
WTLLQEQGTK	S9Y6J1	Keratin like protein	CEX+HIC	6.73	9.5 ± 1.3 <sup>b</sup>
YEELQVTAGR	S9W9S8	F rod domain-containing protein	CEX+HIC	4.15	4.6 ± 1.5 <sup>b</sup>
KHSTKGLGK	S9XLY6	Poly [ADP-ribose] polymerase	CEX+HIC	10.98	6.7 ± 1.2 <sup>b</sup>


<sup>a)</sup> Identified with NCBI BLASTp against *Camelus bactrianus* (taxid:9837) proteins



**Figure1.**



**Figure 2.**



**Figure 3.**





Figure 4.





**Figure 5.**